HaemaLogiX Shines at APAC CGT Excellence Awards with CAR-T Innovation

HaemaLogiX Recognized for Innovation in CAR-T Therapy

HaemaLogiX Ltd, an emerging player in the biopharmaceuticals sector based in Australia, has made headlines by winning the prestigious title of 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT Excellence Awards 2025. The event, which took place in Singapore, celebrated the advancements made in cell and gene therapy across the region. This accolade is a testament to HaemaLogiX's dedication in developing innovative immunotherapies aimed at patients suffering from blood cancers and B-cell disorders.

Professor Rosanne Dunn, the Founder and Chief Scientific Officer of HaemaLogiX, celebrated the achievement as a recognition of both scientific advancements and the commitment of the team. She stated, "This award is wonderful recognition of not just our science, but also the dedication and vision that drives our work. We're honed to be recognized in such exceptional company - a field of the region's top innovators."

The significance of this award lies in its acknowledgment of outstanding contributions to CAR-T therapy, which has shown great promise in transforming health outcomes for patients with multiple myeloma and other significant blood cancers. With approximately 188,000 new multiple myeloma cases diagnosed globally each year, the need for effective therapy solutions is urgent.

What sets HaemaLogiX apart from other players in the field is its unique approach to targeting cancer cells. Utilizing groundbreaking techniques, their immunotherapies are designed to bind to specific antigens found on malignant plasma cells. These unique targets include the kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), which do not exist on normal plasma cells, thereby minimizing off-target toxicity. This innovation not only leads to effective treatment but also preserves the immune function, a significant advantage compared to other existing therapies.

Notably, about 70% of multiple myeloma patients express KMA, while approximately 30% express LMA on their cancerous plasma cells, allowing HaemaLogiX’s innovations to cater effectively to both patient groups. This specificity is crucial as traditional treatments often lead to adverse effects due to their broad targeting, which can compromise the patient's overall immune response.

As Professor Dunn articulated, the journey towards more effective therapies is driven by the substantial unmet medical need for multiple myeloma—currently, many patients experience poor outcomes and limited survival rates. Over half of the patients undergoing standard treatments find that their conditions deteriorate, highlighting the growing necessity for new therapeutic options.

Winning the award at the Asia Pacific CGT Excellence Awards underscores HaemaLogiX's potential to significantly impact the landscape of cancer treatment in the region and possibly around the globe. Dunn emphasized, “We are more determined than ever to advance transformative therapies”, reflecting the company's mission to not only innovate but also to improve health outcomes for patients eagerly awaiting new treatments.

Recognition at such a prestigious platform not only boosts HaemaLogiX's credibility in the biopharmaceutical industry but also strengthens its commitment to addressing one of the most challenging frontiers in cancer therapy. The company is now poised to advance its research and development efforts further, contributing significantly to the field and providing hope for patients suffering from multiple myeloma.

Conclusion

The future of CAR-T therapies is bright, and as HaemaLogiX steps into the spotlight, the entire industry is likely to benefit from the innovations that emerge from their research. With this recognition, the pathway is clear for HaemaLogiX to lead the charge in bringing more effective and targeted treatments to the people who need them most.